CORRECTION -- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 22 2022 - 4:34PM
In a release issued under the same headline earlier today by
uniQure N.V. (NASDAQ: QURE), please note that all the numbers have
been updated. The corrected release follows:
uniQure N.V. (NASDAQ: QURE), a leading gene
therapy company advancing transformative therapies for patients
with severe medical needs, today announced that the Company granted
equity awards to 22 employees as a material inducement to
commencing their employment. The equity grants were approved by the
Company’s board of directors on June 15, 2022 (the “Grant Date”) in
accordance with Nasdaq Listing Rule 5635(c)(4).
In the aggregate, the employees received 39,500
restricted stock units (“RSUs”) and options to purchase 27,500
ordinary shares of uniQure. Each option has an exercise price of
$14.08 per share, the closing price per ordinary share as reported
by Nasdaq on June 15, 2022. Each option has a ten-year term and
will vest over four years, with 25% of the original number of
shares vesting on the first anniversary of the grant date and an
additional 6.25% of the shares vesting in approximately equal
quarterly installments over the twelve successive quarters
following the first anniversary. The RSUs will vest over three
years, with one-third of the RSUs vesting annually on each
successive anniversary of the Grant Date. The vesting of each grant
of options and RSUs is subject to the employee’s continued service
with the Company through the applicable vesting dates.
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary gene therapies to treat patients with hemophilia B,
Huntington's disease, refractory temporal lobe epilepsy, Fabry
disease, and other diseases. www.uniQure.com
uniQure Contacts:
FOR INVESTORS: |
|
FOR MEDIA: |
|
|
|
|
|
|
Maria E. Cantor |
Chiara Russo |
Tom Malone |
Direct: 339-970-7536 |
Direct: 617-306-9137 |
Direct: 339-970-7558 |
Mobile: 617-680-9452 |
Mobile: 617-306-9137 |
Mobile: 339-223-8541 |
m.cantor@uniQure.com |
c.russo@uniQure.com |
t.malone@uniQure.com |
|
|
|
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jun 2024 to Jul 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jul 2023 to Jul 2024